Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HART with Chemotherapy for Metastatic Medulloblastoma
NCT00276666Phase 2Unknown
- Sponsor
- Children's Cancer and Leukaemia Group
- Start
- Nov 2001
- Primary completion
- Mar 2010
- Modality
- DNA Intercalators/Alkylators, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of cisplatin, lomustine and vincristine in medulloblastoma, sponsored by Children's Cancer and Leukaemia Group. Primary endpoint: Toxicity of HART and Chemotherapy. Status: unknown.
02
Drugs
cisplatinlomustinevincristine
03
Conditions
medulloblastoma
Beyond the preview
Go deeper on NCT00276666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276666.